134 related articles for article (PubMed ID: 29621982)
1. Using a nomogram based on preoperative serum fibrinogen levels to predict recurrence of papillary thyroid carcinoma.
Jianyong L; Zhihui L; Rixiang G; Jingqiang Z
BMC Cancer; 2018 Apr; 18(1):390. PubMed ID: 29621982
[TBL] [Abstract][Full Text] [Related]
2. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma.
Shi Y; Su C; Hu H; Yan H; Li W; Chen G; Xu D; Du X; Zhang P
PLoS One; 2018; 13(6):e0198896. PubMed ID: 29949618
[TBL] [Abstract][Full Text] [Related]
3. A Nomogram Based on the Characteristics of Metastatic Lymph Nodes to Predict Papillary Thyroid Carcinoma Recurrence.
Jianyong L; Jinjing Z; Zhihui L; Tao W; Rixiang G; Jingqiang Z
Thyroid; 2018 Mar; 28(3):301-310. PubMed ID: 29439612
[TBL] [Abstract][Full Text] [Related]
4. Individual prediction of lateral neck metastasis risk in patients with unifocal papillary thyroid carcinoma.
Hei H; Song Y; Qin J
Eur J Surg Oncol; 2019 Jun; 45(6):1039-1045. PubMed ID: 30824213
[TBL] [Abstract][Full Text] [Related]
5. A nomogram model based on the preoperative clinical characteristics of papillary thyroid carcinoma with Hashimoto's thyroiditis to predict central lymph node metastasis.
Zhao W; He L; Zhu J; Su A
Clin Endocrinol (Oxf); 2021 Feb; 94(2):310-321. PubMed ID: 32984984
[TBL] [Abstract][Full Text] [Related]
6. The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma.
Song E; Oh HS; Jeon MJ; Chung KW; Hong SJ; Ryu JS; Baek JH; Lee JH; Kim WG; Kim WB; Shong YK; Kim TY
Int J Cancer; 2019 Mar; 144(6):1414-1420. PubMed ID: 30357831
[TBL] [Abstract][Full Text] [Related]
7. Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Zhang N; Cong X; Zhou D; Guo L; Yuan C; Xu D; Su C
Cancer Biomark; 2019; 24(1):7-17. PubMed ID: 30594915
[TBL] [Abstract][Full Text] [Related]
8. Validation and Comparison of Nomograms in Predicting Disease-Specific Survival for Papillary Thyroid Carcinoma.
Lang BH; Wong CK
World J Surg; 2015 Aug; 39(8):1951-8. PubMed ID: 25809064
[TBL] [Abstract][Full Text] [Related]
9. The Clinicopathological Features of Papillary Thyroid Carcinoma Patients with Positive Hepatitis B Surface Antigen.
Zhong Z; Yuan J; Chen X; Chen Z; Du J; Chen Z; Kuang J; Cong S; Li J; Wu Z
Oncol Res Treat; 2020; 43(1-2):27-33. PubMed ID: 31722345
[TBL] [Abstract][Full Text] [Related]
10. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
11. Serum Matrix metalloproteinase-9 (MMP-9) can help identify patients with papillary thyroid cancer at high risk of persistent disease: Value and limitations of a potential marker of neoplasia.
Dobrescu R; Picu C; Caragheorgheopol A; Manda D; Ioachim D; Goldstein A; Badiu C
Cancer Biomark; 2020; 29(3):337-346. PubMed ID: 32716342
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of inflammatory markers LMR, PLR, MPV, FIB in intermediate-and high-risk papillary thyroid carcinoma.
Li C; Li J; Li S; Zhao Y; Liu G; Du R; Dionigi G; Liang N; Sun H
Front Endocrinol (Lausanne); 2022; 13():984157. PubMed ID: 36060974
[TBL] [Abstract][Full Text] [Related]
13. Age greater than 60 years portends a worse prognosis in patients with papillary thyroid cancer: should there be three age categories for staging?
Kauffmann RM; Hamner JB; Ituarte PHG; Yim JH
BMC Cancer; 2018 Mar; 18(1):316. PubMed ID: 29566662
[TBL] [Abstract][Full Text] [Related]
14. Postoperative nomogram for predicting disease-specific death and recurrence in papillary thyroid carcinoma.
Lang BH; Wong CK; Yu HW; Lee KE
Head Neck; 2016 Apr; 38 Suppl 1():E1256-63. PubMed ID: 26332104
[TBL] [Abstract][Full Text] [Related]
15. Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study.
Yu X; Hu F; Yao Q; Li C; Zhang H; Xue Y
BMC Cancer; 2016 Jul; 16():480. PubMed ID: 27418164
[TBL] [Abstract][Full Text] [Related]
16. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma.
Baek SK; Jung KY; Kang SM; Kwon SY; Woo JS; Cho SH; Chung EJ
Thyroid; 2010 Feb; 20(2):147-52. PubMed ID: 19785522
[TBL] [Abstract][Full Text] [Related]
17. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
Dai L; Wang Y; Chen L; Zheng J; Li J; Wu X
World J Surg Oncol; 2017 Jan; 15(1):11. PubMed ID: 28061868
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Forkhead box Q1 correlates with poor prognosis in papillary thyroid carcinoma.
Li Y; Wang HQ; Wang AC; Li YX; Ding SS; An XJ; Shi HY
Clin Endocrinol (Oxf); 2019 Feb; 90(2):334-342. PubMed ID: 30378716
[TBL] [Abstract][Full Text] [Related]
19. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck.
Lee CW; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Ann Surg Oncol; 2015 Jan; 22(1):117-24. PubMed ID: 25034816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
